Snapshot · Huberman Lab
Despite SSRIs being partially effective for OCD, there is very little evidence that the serotonin system itself is causally disrupted in OCD — a recurring theme in psychiatry.
Where this was said
At 28:20 · chapter starts 27:05
Having established CBT's superiority, Huberman pivots to a philosophically important point about SSRIs and psychiatric medicine more broadly. SSRIs do help some OCD patients — reducing symptoms measurably compared to placebo — but the scientific literature provides almost no evidence that OCD is caused by or rooted in serotonin system dysfunction. This is not a minor footnote; it's a fundamental challenge to how psychiatric pharmacology is often understood. Drugs are frequently assumed to reveal the biology of a disorder by the mechanism through which they help. Huberman argues this logic is flawed, and OCD is a clear example: the drug works (somewhat) but the implied causation is unjustified. He broadens this observation to depression, anxiety, and other psychiatric conditions — a recurring theme he believes clinicians and patients deserve to understand.
Combining SSRIs with cognitive behavioral therapy did not produce any further decrease in OCD symptoms compared to CBT alone, confirming CBT as the primary driver of improvement.
SSRIs reduce OCD symptoms in some patients, yet there is almost no evidence that the serotonin system is causally disrupted in OCD. This is a broader problem in psychiatry: drugs that work don't necessarily tell us what's broken.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.